Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Abstract Background Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study was designed to correlate gene expression and mutation profiles with bot...

Full description

Bibliographic Details
Main Authors: Xu Liang, Adrien Briaux, Véronique Becette, Camille Benoist, Anais Boulai, Walid Chemlali, Anne Schnitzler, Sylvain Baulande, Sofia Rivera, Marie-Ange Mouret-Reynier, Laurence Venat Bouvet, Thibaut De La Motte Rouge, Jérôme Lemonnier, Florence Lerebours, Céline Callens
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Journal of Hematology & Oncology
Subjects:
Immunity
Lipid metabolism
Somatic mutation
TILs
RNA sequencing
Targeted NGS
Online Access:http://link.springer.com/article/10.1186/s13045-018-0670-9

Internet

http://link.springer.com/article/10.1186/s13045-018-0670-9

Similar Items